景順健康護理創新基金C-年配息股 美元
197.86美元1.97(0.99%)
2023/10/02更新
本基金的目標是達致長期資本增值。本基金尋求透過主要投資於全球各地的創新健康護理公司的股票及股票相關證券以達致其目標。就本基金而言,健康護理公司包括(但不限於)藥物、生物科技、保健服務及醫療技術及物資等行業公司。投資經理尋求投資於有潛力通過其對產品與服務、科技應用、流程及經營模式或管理的創新方針,令護理質素、獲取護理或護理成本獲得顯著改進的企業。
大型 | |||
---|---|---|---|
中型 | |||
小型 | |||
價值型 | 均衡型 | 增長型 |
Mr. Livengood has been a Vice President of OppenheimerFunds since May 2006 and a Senior Portfolio Manager since January 2014. He was a Senior Research Analyst from May 2006 to January 2014, responsible for the health care, energy and financial services sectors for mid- and small-cap growth accounts. Before joining OppenheimerFunds in May 2006, Mr. Livengood was a vice president and fund analyst with Merrill Lynch Investment Managers. During his tenure at Merrill Lynch he also worked as an investment banking analyst in the Global Media Group and as an associate with Merrill Lynch Ventures.
Henry Wu, Portfolio Manager, has been associated with Invesco and/or its affiliates since 2014 (and was previously associated with Invesco and/or its affiliates from 2006 to 2010). From 2012 to 2013, he was employed by Scopia Capital as a senior analyst. From 2010 to 2012, he was employed by Surveyor Capital/Citdadel Investment Group as an analyst.
基金篩選
沒有符合 ”“ 的搜尋結果。